Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have added about 11.4% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Catalyst due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

How Have Estimates Been Moving Since Then?

It turns out, estimates review have trended upward during the past month.

VGM Scores

At this time, Catalyst has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. Following the exact same course, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Catalyst has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry Player

Catalyst belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, United Therapeutics (UTHR), has gained 3.8% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.

United Therapeutics reported revenues of $794.4 million in the last reported quarter, representing a year-over-year change of +17.2%. EPS of $6.63 for the same period compares with $6.17 a year ago.

For the current quarter, United Therapeutics is expected to post earnings of $6.76 per share, indicating a change of +15.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.9% over the last 30 days.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for United Therapeutics. Also, the stock has a VGM Score of A.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research